Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Analysis of Revascularisation in Ischemic Stroke With EmboTrap (ARISE)

16 de noviembre de 2018 actualizado por: Neuravi Limited

A.R.I.S.E. Analysis of Revascularisation in Ischemic Stroke With EmboTrap: Post Marketing Observational Study of CE Marked EmboTrap Mechanical Thrombectomy Device

A.R.I.S.E. is a post approval observational study using standard care. The purpose of this study is to collect information about the ability of the EmboTrap device to remove blood clots from the brain, and the associated performance characteristics and clinical outcomes. No formal hypothesis testing is needed as no comparisons are planned within the study. Instead, estimates of each population parameter of interest for all primary and secondary endpoints will be provided using appropriate confidence intervals.

Descripción general del estudio

Tipo de estudio

De observación

Inscripción (Actual)

40

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Kiel, Alemania
        • Universitätsklinikum Kiel
      • Aarhus, Dinamarca
        • Aarhus University Hospital
      • Barcelona, España
        • Hospital Clínico de Barcelona
      • Dublin, Irlanda
        • Beaumont Hospital
      • Solna, Suecia, 17176
        • Karolinska Institutet

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 80 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Ischemic stroke patients

Descripción

Inclusion Criteria:

  • The patient or the patient's legally authorized representative has signed and dated an Informed Consent Form.
  • Aged between 18 years and 80 years (inclusive).
  • A new focal disabling neurologic deficit consistent with acute cerebral ischemia.
  • NIHSS score ≥8 and ≤25.
  • Pre-ictal mRS score of 0 or 1.
  • Angiographic confirmation of an occlusion of an ICA (including T and L occlusions), M1 or M2, MCA, or BA with TICI flow of 0-1.
  • Confirmation by the interventionalist, after screening CT or MRI, that the treatment site can be accessed with the Neuravi device.
  • The interventionalist estimates that at least one deployment of the Neuravi device can be completed within 5 hours from the onset of symptoms, or if time of onset of symptoms is unknown or > 5 hours, patients can be included using imaging with the following criteria:

    1. MRI criterion: ASPECTS 8 to 10, or,volume of diffusion restriction ≤30 mL and mismatch between perfusion reduction and diffusion restriction present.
    2. CT criterion: ASPECTS 8 to 10 on baseline CT or CTA-source images, or, volume of significantly lowered CBV ≤30 mL and mismatch between perfusion reduction and low CBV present.

Exclusion Criteria:

  • Life expectancy of less than 6 months.
  • Females who are pregnant or lactating.
  • History of severe allergy to contrast medium.
  • Has suffered a stroke in the past three months.
  • The patient presents with an NIHSS score <8 or >25 or is physician assessed as being in a clinically relevant uninterrupted coma.
  • Use of warfarin anticoagulation with International Normalized Ratio (INR) > 3.0.
  • Platelet count < 50,000.
  • Glucose < 50 mg/dL.
  • Heparin use in previous 24 hours with PTT or ACT > 2X normal.
  • Any known hemorrhagic or coagulation deficiency.
  • Computed tomography (CT) or Magnetic Resonance Imaging (MRI) evidence of recent/ fresh hemorrhage on presentation.
  • For basilar artery occlusion, extended early ischemic changes as confirmed by pc-ASPECTS ≤ 7 on baseline CT or CTA-source images, or extensive DWI lesions in the midbrain or pons regions on pre-treatment MRI.
  • Baseline CT or MRI showing mass effect or intracranial tumor (except small meningioma).
  • Excessive arterial tortuosity that precludes the study device from reaching the target vessel.
  • A proximal stenosis or complete occlusion that cannot, as judged by the responsible interventionalist, be treated safely or which prevents access to the occluded vessel with the Neuravi device.
  • Evidence of active infection.
  • Known cancer with metastases
  • Current use of cocaine or other vasoactive substance.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: Grupo
  • Perspectivas temporales: Futuro

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
EmboTrap® Revascularization Device
The EmboTrap® Revascularization Device is the investigational device
Otros nombres:
  • Embo Trampa

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Proportion of Revascularisation Following the Use of the Neuravi Device.
Periodo de tiempo: Day 1

Revascularisation is defined as achieving a modified Thrombolysis in Cerebrovascular Infarction (mTICI) score of 2b or greater.

mTICI is a 6-point grading system for determining the response of thrombolytic therapy for ischaemic stroke:

mTICI 0 = No perfusion

mTICI 1 = Penetration but not perfusion

mTICI 2a = Some perfusion with distal branch filling of <50% of territory visualized

mTICI 2b = Substantial perfusion with distal branch filling of ≥50% of territory visualized

mTICI 2c = Near-complete perfusion

mTICI 3 = Complete perfusion

Day 1

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Time to Revascularization
Periodo de tiempo: Day 1
Defined as time from groin puncture to visualization of final angiographic result.
Day 1
Mortality Post Procedure
Periodo de tiempo: 7 and 90(±14) days post procedure
All procedure related mortality (i.e. directly traceable to a procedure related SAE).
7 and 90(±14) days post procedure
Serious Adverse Device Related Effects (SADE)
Periodo de tiempo: 24(-8/+12) hours Post Procedure
SADE is defined as vessel perforation or vessel dissection, which is attributable to the Neuravi device, or where the Neuravi device cannot be ruled out as the cause.
24(-8/+12) hours Post Procedure
Symptomatic ICH
Periodo de tiempo: 24(-8/+12) hours Post Procedure

Symptomatic ICH rate within 24 hours (range: 16 to 36 hours) post-procedure. Symptomatic intracranial haemorrhage (parenchymatous haemorrhage type 2), at post-treatment scan combined with neurological deterioration (C2) leading to an increase of 4 points or more on the NIH Stroke Scale.

The NIHSS is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. NIHSS scores range from 0 - 42. A score of 0 indicates no stroke symptoms. Higher scores indicate incremental levels of neurological impairment.

24(-8/+12) hours Post Procedure
Clinical Outcome at 90 Days
Periodo de tiempo: 90(±14) days Post Procedure

A good clinical outcome will be judged to be a mRS score of ≤2 at 90(±14) days.

mRS is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. mRS scores range from 0 to 6:

mRS 0 = No symptoms.

mRS 1 = No significant disability.

mRS 2 = Slight disability.

mRS 3 = Moderate disability.

mRS 4 = Moderately severe disability.

mRS 5 = Severe disability.

mRS 6 = Dead.

90(±14) days Post Procedure
Rate of New Territory Embolization
Periodo de tiempo: 24(-8/+12) hours Post Procedure
Embolization, or thrombus dislocation, into a previously uninvolved vascular territory as evaluated from angiographic images by the Angiography Core Lab and the Data Safety Monitoring Board.
24(-8/+12) hours Post Procedure
Evidence of Infarction
Periodo de tiempo: 24(-8/+12) hours Post Procedure
Infarction, of a previously uninvolved vascular territory, as evaluated from 24hr Computed Tomography imaging by the Angiography Core lab.
24(-8/+12) hours Post Procedure

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Dr. Tommy Andersson, Karolinska Institutet
  • Investigador principal: Prof. Dr. Heinrich Mattle, University Hospital Inselspital, Berne

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Enlaces Útiles

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de noviembre de 2014

Finalización primaria (Actual)

1 de mayo de 2016

Finalización del estudio (Actual)

1 de enero de 2018

Fechas de registro del estudio

Enviado por primera vez

10 de julio de 2014

Primero enviado que cumplió con los criterios de control de calidad

11 de julio de 2014

Publicado por primera vez (Estimar)

15 de julio de 2014

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

11 de marzo de 2019

Última actualización enviada que cumplió con los criterios de control de calidad

16 de noviembre de 2018

Última verificación

1 de noviembre de 2018

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Dispositivo de revascularización EmboTrap®

3
Suscribir